PPA
BVS icon

Parametric Portfolio Associates’s Bioventus BVS Stock Holding History

Parametric Portfolio Associates’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,355
Closed -$179K – 3685
2021
Q4 		$179K Buy
+12,355
New +$176K ﹤0.01% 3448

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
JIC
Juniper Investment Company New York $378M AUM 95.37% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
NI
Nuance Investments Kansas City, Missouri $588M AUM 6.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Parametric Portfolio Associates's BVS Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Bioventus (BVS) in Q1 2022, closing a stake of 12,355 shares — an estimated $179K sold.

Parametric Portfolio Associates first reported a position in BVS in Q4 2021 and held it in 1 quarter. The position peaked at $179K in Q4 2021. 105 funds tracked by Wall St. Rank hold BVS as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Bioventus position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 12,355 Bioventus shares in Q1 2022, an estimated $179K.
  • Parametric Portfolio Associates first reported a position in Bioventus in Q4 2021 and held it in 1 quarter.
  • Parametric Portfolio Associates's Bioventus position peaked at $179K in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Bioventus as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.